CO-ADMINISTRATION OF Toxoplasma gondii SERINE- PROTEASE INHIBITOR-1 WITH ALLERGEN INDUCES REGULATORY CELLS IN ASTHMATIC MICE

ARIADNA SOTO, IGNACIO FENOY, VANESA SÁNCHEZ, MARÍA DE LOS ANGELES ALDIRÍCO, MATÍAS PERRONE SIBILIA, MARIANO PICCHIO, NADIA ARCON, FLORENCIA GIORGIO; VALENTINA MARTIN; ALEJANDRA GOLDMAN

Congreso; Reunión Conjunta de Sociedades de Biociencias; 2017

By using a therapeutic experimental asthma model we previouslyshowed that treatment with T. gondii serine protease inhibitor-1(TgPI-1) significantly reduced airway hyper-responsiveness and inflammation.Moreover, co-administration of TgPI-1 with the allergenshowed an enhanced improvement compared with the administrationof TgPI-1 alone. Besides, we observed that allergen-specificTh1 and Th2 responses were diminished. Based on these results,in the present study we sought to explore whether regulatory cellsmay account for the effect of TgPI-1. For this purpose we first evaluatedif TgPI-1 treatment modulates allergen-specific T cell proliferation.BALB/c mice ip. sensitized with ovalbumin (OVA)/Alumand aerosol challenged, were intranasally treated with TgPI-1 (PI)or TgPI-1+OVA (OPI). Controls included non-sensitized mice (N),and asthmatic mice treated with PBS (O) or with OVA (OO). Oneweek after the treatment, mice were re-challenged. Only mice treatedwith OPI showed a significant reduction in thoracic lymph nodecells OVA-specific proliferation (OPI vs OO; p